Tempest Therapeutics signs exclusive option deal with Senlang for CD7-targeted in vivo CAR-T platform
TPST•TPST•TPST•TPST•Early observations at the highest evaluable dose showed in vivo CAR-T generation and expansion.
As of Aug. 25, 2026, no Grade 3+ cytokine release syndrome or neurotoxicity was reported at evaluated doses.
The deal adds a lentiviral approach alongside Tempest’s CD7-targeted lipid nanoparticle platform, which is planned to enter the clinic later in 2026.
Tempest Therapeutics entered an exclusive option agreement with Hebei Senlang Biotechnology to license a CD7-targeted lentiviral in vivo CAR-T platform.
The option covers a portfolio led by a BCMA/GPRC5D dual-targeting candidate in Phase 1 dose escalation for relapsed or refractory multiple myeloma.
